Healthcare >> Analyst Interviews >> November 17, 2008
Reni Benjamin is Managing Director and Senior Biotechnology Analyst at Rodman &
Renshaw, LLC. His expertise and company coverage consists of small cap companies
in the oncology and stem cell sectors. He has previously been ranked among the
top analysts for recommendation performance and earnings accuracy by StarMine
and has been cited in a variety of sources including The Wall Street Journal,
BusinessWeek, Financial Times, Dow Jones Newswire, and SmartMoney. He has also
made appearances on Bloomberg television/radio and CNBC. Prior to joining Rodman
& Renshaw, he was an Associate Analyst in Needham and Company's biotechnology
equity research department. Prior to that, he earned his Doctorate in
Biochemistry by discovering and characterizing a novel gene implicated in germ
cell development. His expertise includes biochemistry, functional genomics, gene
therapy and molecular biology. He has presented at various regional and
international conferences and published in peer-reviewed journals. He received
his PhD from the University of Alabama at Birmingham and his Bachelor of Science
degree in Biology from Allegheny College. Profile
Dr. Benjamin: In my opinion, that decision depends on what type of investor you
are. Clearly there are those investors that
